FDA Issues New Label Change for Codeine and Tramadol
Decades of research has led to a flurry of new warnings.
The FDA is now warning against the use of codeine and tramadol in children under the age of 12. The warning is due to a higher incidence of slowed or difficult breathing and death in children.
The new labeling for products containing codeine adds a warning that they should not be used to treat cough in children under 12. Labeling for tramadol states that it should not be used to treat pain in children under 12 or used in children under 18 to treat pain after a tonsillectomy and/or adenoidectomy.
The FDA is also adding a warning recommending against the use of these drugs in children between 12 and 18 who have conditions such as obstructive sleep apnea or severe lung disease, because of the increased risk of severe breathing problem. Finally, the labels also include a strengthened warning to mothers that breastfeeding is not recommended when taking either codeine or tramadol, as this can cause serious adverse reactions in their babies or toddlers.
Related article: Children prescribed codeine in ERs despite risks
The new warnings and contraindications come after the 2013 restriction of codeine use in children under 18 to treat pain after a tonsillectomy and/or adenoidectomy. In July and September of 2015, the FDA issued a Drug Safety Communications warning about the risk of serious breathing problems in children with ultra-rapid metabolism of codeine and tramadol, as this could lead to a quick rise to unsafe levels of the drugs.
The FDA reviewed data from January 1969 to May 2015, and identified 64 cases of serious breathing problems (including 24 deaths) with codeine-containing medicines in children younger than 18 years. The FDA also found nine cases of difficulty breathing (including three deaths) with use of tramadol in children under 18 between January 1969 and March 2016. The majority of the serious side effects occurred in children under 12.
The FDA has said that it will continue to monitor the issue, and is considering regulatory action for OTC codeine products that are available in some states.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
